149 related articles for article (PubMed ID: 38710335)
1. Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma.
Wang C; Li Z; Zhai H; Shen X; Li F; Zhang Q; Li D; Hou H
Eur J Pharm Sci; 2024 Jul; 198():106789. PubMed ID: 38710335
[TBL] [Abstract][Full Text] [Related]
2. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
Ma L; Zhang G; Miao XB; Deng XB; Wu Y; Liu Y; Jin ZR; Li XQ; Liu QZ; Sun DX; Testa JR; Yao KT; Xiao GH
FEBS J; 2013 May; 280(9):2027-41. PubMed ID: 23461856
[TBL] [Abstract][Full Text] [Related]
5. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
6. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
[TBL] [Abstract][Full Text] [Related]
7. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
8. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR therapies in nasopharyngeal carcinoma.
Chen X; Liang R; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110649. PubMed ID: 32836074
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
11. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
[TBL] [Abstract][Full Text] [Related]
12. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
13. GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
Li X; Wang H; Yang X; Wang X; Zhao L; Zou L; Yang Q; Hou Z; Tan J; Zhang H; Nie J; Jiao B
Cancer Lett; 2021 Aug; 514():90-102. PubMed ID: 34023418
[TBL] [Abstract][Full Text] [Related]
14. Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma.
Yang J; Qin L; Zhou S; Li J; Tu Y; Mo M; Liu X; Huang J; Qin X; Jiao A; Wei W; Yang P
J Ethnopharmacol; 2024 Apr; 323():117667. PubMed ID: 38159821
[TBL] [Abstract][Full Text] [Related]
15. A novel anthraquinone‑quinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1.
Kang J; Zhong Y; Tian W; Li J; Li X; Zhai L; Hou H; Li D
Int J Oncol; 2021 May; 58(5):. PubMed ID: 33760108
[TBL] [Abstract][Full Text] [Related]
16. Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition.
Xia L; Zheng Z; Liu JY; Chen YJ; Ding J; Hu GS; Hu YH; Liu S; Luo WX; Xia NS; Liu W
Cancer Immunol Res; 2021 Jun; 9(6):707-722. PubMed ID: 33875483
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
18. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
19. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
20. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
